We are all in this together
With COVID-19 our thoughts turn to the patients and the global communities affected by this epidemic and the healthcare professionals on the front line.
Eisbach believes that developing innovative approaches are essential contributions that our industry can make toward addressing the impact of COVID-19. We believe that as an innovative drug discovery startup, it is our duty and responsibility to act.
Eisbach joins worldwide efforts to combat the pandemic.
Acting now
Eisbach is adding an R&D team aiming to identify new drugs targeting two essential and novel molecular targets in SARS-CoV-2. Such medicines would help treat the infected, reduce symptoms and tissue damage, and thus hopefully reduce mortality.
We aim to promote better health of citizens
Targeting unique and novel mechanisms for COVID-19 therapy
We aim to identify small molecules targeting novel, disease-relevant functions in SARS-CoV-2. Using our innovative platform, we are currently developing inhibitors against two relevant and essential SARS-CoV-2 proteins, for which the founding team has pioneering, worldwide expertise. Since these proteins are essential for the replication of the viral SARS-CoV-2 genome and to suppress the host’s immune system, they represent highly promising drug targets.
Our AI-driven docking algorithm has already validated a non-ATP-competitive binding pocket and identified SARS-CoV-2 inhibitors which we will now rapidly progress to pre-clinical PoC. Such medicines would help treat the infected, reduce symptoms and thus hopefully, reduce mortality. Eisbach is poised to develop drugs to reduce the burden of COVID- 19 and related CoVs!
Pioneering expertise
Novel, cell-active small molecule inhibitors
Drug discovery supported by AI
